Dr Tochi Okwuosa: We Need More Data on Cardio-Toxicity From Radiation
November 8th 2022Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.
Read More
Dr Kausik Ray: ORION-3 Data Show Inclisiran Produces Durable Sustained LDL-C Reduction
November 7th 2022Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).
Read More
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, professor of medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the results of the recently halted FRESH trial, why there is such a great need for new antihypertensive agents, and possible contributory factors to outcome disparities between Black and White patients.
Read More
Guideline-Directed Medical Therapies Focus on Adherence, Cost in Patients With HFrEF
November 7th 2022Posters presented at the American Heart Association's Scientific Sessions elaborated on the results of out-of-pocket expenses and adherence for guideline-directed medical therapies in patients with heart failure with reduced ejection fraction (HFrEF).
Read More
Dr Mikhail Kosiborod Discusses the Clinical Importance of the Latest DELIVER Data on Dapagliflozin
November 7th 2022The DELIVER trial is the largest trial to date of SGLT2 inhibitor use in heart failure, and these latest data on dapagliflozin in heart failure with mildly reduced or preserved ejection fraction show an extensive benefit on health status, noted Mikhail Kosiborod, MD, cardiologist at St. Luke's Mid America Heart Institute in Kansas City, Missouri.
Read More
Dr Stephen J. Greene: New VICTORIA Trial Data Show Benefit to Vericiguat In-Hospital Initiation
November 7th 2022The latest real-world clinical practice data from the VICTORIA trial of vericiguat bolster previous data on the medication’s benefit by showing that 92% of patients hospitalized for a worsening heart failure event would be eligible to start the therapy and that doing so would reduce their risk of heart failure hospitalization and cardiovascular death, noted Stephen J. Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.
Read More
The VICTORIA Trial: What It Means for HFrEF Treatment
November 7th 2022Posters presented at the American Heart Association conference in Chicago, Illinois, evaluated the insights from the VICTORIA trial and their generalizability to patients hospitalized with heart failure with reduced ejection fraction (HFrEF).
Read More
Dr Michael Portman: Edoxaban Facilitates Easier Treatment, Improved QOL in Pediatric Cardiac Disease
November 6th 2022In the ENNOBLE-ATE trial, Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's, and his team evaluated the safety and efficacy of edoxaban, a direct oral anticoagulant previously only used among adult patients, among pediatric patients with cardiac disease.
Read More
Dr Douglas Mann Discusses Novel CRISPR/Cas9 Findings in ATTR Amyloid Cardiomyopathy
November 6th 2022Douglas L. Mann, MD, professor of medicine at Washington University School of Medicine in St. Louis and editor-in-chief of JACC: Basic to Translational Science discussed the first set of data reported on NTLA-2001, a novel investigative intravenous agent that targets the TTR gene and TTR protein levels, which have been shown to play a role in development of cardiac transthyretin (ATTR) amyloidosis.
Read More
KCCQ-12 Improved Accuracy of Health Status Assessment in Heart Failure Clinic
November 5th 2022Research presented at the American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, found that the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) was able to assess patients’ symptoms more accurately for clinicians.
Read More
Data Presented at AHA Shows Medicare's HRRP Only Cut Readmissions for the Wealthy
November 5th 2022Posters presented at the American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, found that the neighborhood income and socioeconomic status had an effect on heart failure and all-cause readmission rates.
Read More
Dr Deepak Bhatt Explains Interim Results of REVERSE-IT Trial
November 16th 2021Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, explains the interim findings of the REVERSE-IT trial that were presented at the 2021 AHA Scientific Sessions.
Read More
New Data Presented for Finerenone, Vericiguat, and SGLT2 Inhibitors at HF Session
November 16th 2021A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.
Read More
Dr Derek Chew on the VICTORIA Trial and the Cost-effectiveness of Vericiguat
November 15th 2021The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.
Read More
Dr Ian Neeland Describes Sleep Therapies for Diabetic Vascular Complications
November 15th 2021Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. He summarized a talk he gave at the 2021 AHA Scientific Sessions, “Disrupted Sleep in Diabetic Vascular Complications."
Read More
Despite ample trial evidence that empagliflozin is effective across a broad spectrum of chronic heart failure, some doctors had been reluctant to prescribe in an acute hospital setting for safety reasons. EMPULSE findings presented at the 2021 AHA Scientific Sessions address this concern.
Read More
Pfizer, Moderna Execs Explore COVID-19 Vaccines and CV Health at AHA
November 14th 2021A session at the American Heart Association Scientific Sessions covered the data behind concerns about mRNA vaccines for COVID-19 and myocarditis. Then, leaders from Pfizer and Moderna discussed opportunities the technology offers.
Read More
Dr Clyde Yancy: Health Inequality Is Rooted in Our Community, Policy
November 13th 2021Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine, explains the connections between health care equity and advances in treatment for heart failure and how the United States' policy and science agenda can address them.
Read More
Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA, is an assistant professor in the University of Arizona College of Medicine--Tucson, Division of Cardiology. She is presenting a talk at the American Heart Association (AHA) Scientific Sessions, "COVID-19 as a Catalyst to Address Disparities in Cardiovascular Outcomes and Inequities in Cardiovascular Care Delivery.”
Read More
Health Equity, Heart Failure, and Technology on Agenda at AHA Scientific Sessions
November 11th 2021Solutions for health equity, treatments for heart failure, and the use of technology in prevention and patient care are just some of the topics on the agenda for the 2021 American Heart Association (AHA) Scientific Sessions, which will take place Saturday through Monday in a virtual format.
Read More
Dr Seth Martin on the mTECH Center and Digital Divides
November 11th 2021Seth Martin, MD, MHS, associate professor of medicine at Johns Hopkins University and co-director of the Center for Mobile Technologies to Achieve Equity in Cardiovascular Health (mTECH Center), gives a preview of his presentation on digital divides at the American Heart Association (AHA) Scientific Sessions 2021.
Read More
Dr Tiffany Powell-Wiley on Social Factors of Obesity and Cardiovascular Disease
November 10th 2021Tiffany Powell-Wiley, MD, MPH, a Stadtman investigator and chief of the Social Determinants of Obesity and Cardiovascular Risk Laboratory at the National Heart, Lung, and Blood Institute, with a joint appointment at the National Institute on Minority Health and Health Disparities, discusses ongoing trials and the American Heart Association’s Scientific Statement on social determinants of obesity and cardiovascular disease.
Read More